$INTI
Inhibitor Therapeutics, Inc.

2020 Q1 Form 10-K Financial Statement

#000119312520090201 Filed on March 30, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2018 Q4 2018
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $288.0K $674.2K $1.931M
YoY Change -51.58% 82.23% -33.23%
% of Gross Profit
Research & Development $97.46K $655.3K $2.634M
YoY Change -50.47% 23.64% 18.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $385.4K $1.330M $4.564M
YoY Change -51.31% 46.1% -10.84%
Operating Profit -$385.4K -$4.564M
YoY Change -51.31% -10.84%
Interest Expense $1.030K $3.320K $14.03K
YoY Change -80.6% -21.49%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$384.4K -$1.326M -$4.550M
YoY Change -51.11% 47.35% -10.8%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$384.4K -$1.326M -$4.550M
YoY Change -51.11% 47.35% -10.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.038K -$3.585K -$12.30K
COMMON SHARES
Basic Shares Outstanding 370.4M 370.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $302.7K $1.109M $1.109M
YoY Change -73.23% 226.09% 222.2%
Cash & Equivalents $302.7K $1.109M $1.109M
Short-Term Investments
Other Short-Term Assets $48.24K $41.30K $41.30K
YoY Change 4.53% -86.68% -86.75%
Inventory
Prepaid Expenses $48.24K $41.30K
Receivables
Other Receivables
Total Short-Term Assets $350.9K $1.150M $1.150M
YoY Change -70.18% 75.37% 75.37%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $46.38K $82.99K $82.99K
YoY Change -38.71% -26.09% -26.09%
Total Long-Term Assets $46.38K $82.99K $82.99K
YoY Change -38.71% -26.09% -26.09%
TOTAL ASSETS
Total Short-Term Assets $350.9K $1.150M $1.150M
Total Long-Term Assets $46.38K $82.99K $82.99K
Total Assets $397.3K $1.233M $1.233M
YoY Change -68.28% 60.54% 60.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $154.2K $384.8K $384.8K
YoY Change -37.08% -28.06% -28.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $345.9K $700.7K $700.7K
YoY Change 6.49% 16.49% 16.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $500.0K $500.0K
YoY Change 100.0%
Total Long-Term Liabilities $3.000M $500.0K $500.0K
YoY Change 100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $345.9K $700.7K $700.7K
Total Long-Term Liabilities $3.000M $500.0K $500.0K
Total Liabilities $3.346M $1.201M $1.201M
YoY Change 83.36% 99.61% 99.61%
SHAREHOLDERS EQUITY
Retained Earnings -$56.35M -$52.98M
YoY Change 4.7% 9.75%
Common Stock $49.44M $49.05M
YoY Change 0.32% 1.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.949M $32.35K $32.35K
YoY Change
Total Liabilities & Shareholders Equity $397.3K $1.233M $1.233M
YoY Change -68.28% 60.54% 60.54%

Cashflow Statement

Concept 2020 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$384.4K -$1.326M -$4.550M
YoY Change -51.11% 47.35% -10.8%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$501.1K -$832.1K -$3.708M
YoY Change -48.76% 54.1% 27.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 500.0K 4.473M
YoY Change -100.0% -223.28%
NET CHANGE
Cash From Operating Activities -501.1K -832.1K -3.708M
Cash From Investing Activities
Cash From Financing Activities 0.000 500.0K 4.473M
Net Change In Cash -501.1K -332.1K 764.6K
YoY Change -2376.72% -38.5% -111.69%
FREE CASH FLOW
Cash From Operating Activities -$501.1K -$832.1K -$3.708M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Assets
Assets
1233001
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53700
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82992
CY2019Q4 us-gaap Assets
Assets
899966
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2019Q4 us-gaap Assets Current
AssetsCurrent
846266
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1150009
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Liabilities
Liabilities
3431101
CY2018Q4 us-gaap Liabilities
Liabilities
1200650
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42450
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41296
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
315940
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
384829
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49384953
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49015120
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37045
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37008
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
899966
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1233001
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
431101
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
700650
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14339
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
215876
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55913999
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52980643
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
99945
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6425461
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-2747896
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-4564257
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14540
CY2018 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14027
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-2733356
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-4550230
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370432295
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369812939
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1208075
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2633567
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1539821
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1930690
CY2019 us-gaap Operating Expenses
OperatingExpenses
2747896
CY2018 us-gaap Operating Expenses
OperatingExpenses
4564257
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370084064
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370084064
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
3960866
CY2018 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
543098
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
269924
CY2019 us-gaap Profit Loss
ProfitLoss
-2733356
CY2018 us-gaap Profit Loss
ProfitLoss
-4550230
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
269924
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
543098
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-28138
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-299651
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-270425
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-785
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2705719
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3708266
CY2018 hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
3960866
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-304897
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
764600
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
300000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3424000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1616842
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5002685
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
54618390
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.14
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y6M
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
500000
CY2019 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
200000
CY2019 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2933356
CY2018 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4706723
CY2018 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
156493
CY2019 hppi Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
CY2019 us-gaap Stock Issued1
StockIssued1
99946
CY2019 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
100822
CY2018 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99946
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2400822
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4472866
CY2018 us-gaap Stock Issued1
StockIssued1
56547
CY2019 us-gaap Payments Of Dividends
PaymentsOfDividends
99178
CY2018 hppi Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
500000
CY2018 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
56547
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
156493
CY2019 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
200000
CY2019 hppi Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2019 hppi Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
0.70
CY2019 hppi Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1260
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1260
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2794000
CY2019Q4 hppi Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Aggregate Intrinsic Value
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsAggregateIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.05
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.24
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2016000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.28
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.15
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.19
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3195527
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1671000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1331842
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2208685
CY2019Q4 hppi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerShare
0.07
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
1260
CY2019Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
6228000
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2019 dei Security12g Title
Security12gTitle
Common stock
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-574005
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-955548
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-112934
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-188002
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
40085
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-24357
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
646854
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1167907
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
736325
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
736325
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5807112
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
339052
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
310682
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33943
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33943
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2742
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2607
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7537523
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6890669
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7537523
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6890669
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
CY2018Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00
CY2019Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000

Files In Submission

Name View Source Status
0001193125-20-090201-index-headers.html Edgar Link pending
0001193125-20-090201-index.html Edgar Link pending
0001193125-20-090201.txt Edgar Link pending
0001193125-20-090201-xbrl.zip Edgar Link pending
d858310d10k.htm Edgar Link pending
d858310dex231.htm Edgar Link pending
d858310dex311.htm Edgar Link pending
d858310dex312.htm Edgar Link pending
d858310dex321.htm Edgar Link pending
d858310dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20191231.xml Edgar Link completed
hppi-20191231.xsd Edgar Link pending
hppi-20191231_cal.xml Edgar Link unprocessable
hppi-20191231_def.xml Edgar Link unprocessable
hppi-20191231_lab.xml Edgar Link unprocessable
hppi-20191231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending